November 22nd, 2019
This conference has already taken place.
Description
In the past 2 years, there has been an abundance of new data on both old and new therapies for treating osteoporosis and metabolic bone disease. This data has included new looks at medications that have been around for years, as well as the successful development of new medications such as abaloparatide and romosozumab, the latter of which was FDA approved just in the first week of April, 2019. There are many questions that exist such as the best way to use these medications, should they be used in sequence, and how should that be determined? Other questions are about the side effects of medications - how to anticipate those and avoid them. Many people wonder if certain medications would be better used in combination rather than sequentially. We will specifically review the very recently published guidelines by the Endocrine Society, "Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline" and we anticipate it will influence practice patterns with increased use of evidence-based strategies the very next day of practice.
For pricing information, see pricing tab below.
Dates and Times
Start: 11/22/2019 12:00 AM
End: 11/22/2019 12:00 AM
Objectives
At the conclusion of this activity, learners will be able to:
Clarify the role of various pharmacologic therapies to treat osteoporosis and to assist the practitioner in using a variety of strategies to approach and treat patients with osteoporosis in a patient-centered fashion.
Evaluate patients with high risk for fracture in regards to treatment options and considering secondary causes of bone loss. They will also have the tool of the new Endocrine Society Guidelines on the Treatment of Postmenopausal Osteoporosis to assist them in their day-to-day clinical care.
Recognize the challenges that patients with advanced renal failure present to the practitioner in identifying, understanding and treating osteoporosis in this unique population. The latest guidelines for treating this group of patients has been updated and will be reviewed.
Explain bone densitometry as they view actual images of bone density tests and become more competent in personally analyzing these images.
Employ the most recent recommendations from the National Osteoporosis Foundation including tools for the advancement of communication between providers and practitioners to improve a discourse with our patients, ultimately resulting in improved understanding, compliance and outcomes, including fracture reduction.
Review the subtle and sometimes tricky presentation of patients with rare bone disease. Participants will be better able to evaluate these patients and have information about recently approved medications to treat many of these rare bone diseases.
Review the most recent guidelines regarding the evaluation of primary hyperparathyroidism, the most common cause of hypercalcemia. Participants of this CME event will be better able to differentiate patients who require surgical intervention, versus those that would do well with more conservative therapy. We will also introduce the role of genetics in this interesting group of diseases.
Pricing
| Tier | Price |
|---|---|
| Physician | $200.00 |
| Non-Physician | $125.00 |
Conference Files
| File | Link |
|---|---|
|
Brochure and Agenda Click "Download" to see the conference agenda |
Download |
Speakers
Location
The Fawcett Center
2400 Olentangy River Rd
Columbus , OH 43210
Accreditation Statement
The Ohio State University is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The Ohio State University designates this live activity for a maximum of 8.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.